The recent first global approval[1] of durvalumab in the US has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[2], based on the development milestones tracked in AdisInsight.[3]

In November, 2017, durvalumab (Imfinzi™), developed by AstraZeneca via Medimmune, was also approved in Canada for the treatment of advanced bladder cancer (late stage and/or metastatic disease) as monotherapy in previously treated patients (second-line or greater).[4]

Dr. Sebastien Hotte, Medical Oncologist and Associate Professor, Department of Oncology, McMaster University said that “Typically, patients with advanced bladder cancer begin with standard platinum-containing chemotherapy.” He further explained that, “those who experience progression in their cancer either during or following chemotherapy are left with few other treatment options. Health Canada’s approval of Imfinzi offers a new option to those currently living with this disease, or those who may find themselves with limited options in the future.” [4]

For further information related to the first approval of Durvalumab please visit Drugs[2], or to learn more about the overall development of durvalumab across all indications visit AdisInsight. [3]

Image credit:  Ivelin Radkov / Fotolia

Leave a Reply